These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12712489)

  • 21. [Nephroblastomas (Wilms' tumors) and special variations of nephroblastomas].
    Schmidt D
    Veroff Pathol; 1989; 133():1-174. PubMed ID: 2556868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 23-year experience with malignant renal tumors in infancy and childhood.
    Tröbs RB; Hänsel M; Friedrich T; Bennek J
    Eur J Pediatr Surg; 2001 Apr; 11(2):92-8. PubMed ID: 11371043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histological analysis of aggressiveness and responsiveness in Wilms' tumor.
    Beckwith JB; Zuppan CE; Browning NG; Moksness J; Breslow NE
    Med Pediatr Oncol; 1996 Nov; 27(5):422-8. PubMed ID: 8827069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterogeneity of disease classified as stage III in Wilms tumor: a report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).
    Spreafico F; Gandola L; D'Angelo P; Terenziani M; Collini P; Bianchi M; Provenzi M; Indolfi P; Pession A; Nantron M; Di Cataldo A; Marchianò A; Catania S; Fossati Bellani F; Piva L;
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):348-54. PubMed ID: 21075548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics and outcome of Wilms tumors with a favorable histology in Japan: a report from the Study Group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan.
    Suita S; Kinoshita Y; Tajiri T; Hara T; Tsuneyoshi M; Mizote H; Inada H; Takamatsu H; Kawano Y; Inomata Y; Nagasaki A; Ono Y; Handa N; Okamura J; Ishii E; Kawakami K;
    J Pediatr Surg; 2006 Sep; 41(9):1501-5. PubMed ID: 16952581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features.
    Takahashi M; Yang XJ; Lavery TT; Furge KA; Williams BO; Tretiakova M; Montag A; Vogelzang NJ; Re GG; Garvin AJ; Söderhäll S; Kagawa S; Hazel-Martin D; Nordenskjold A; Teh BT
    Cancer Res; 2002 Nov; 62(22):6598-605. PubMed ID: 12438255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of p53 expression in Wilms' tumor in children.
    Skotnicka-Klonowicz G; Kobos J; Łoś E; Trejster E; Szymik-Kontorowicz S; Daszkiewicz P
    Med Sci Monit; 2001; 7(6):1224-9. PubMed ID: 11687734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of bilateral Wilms tumor over three decades: The perspective of a single center.
    User IR; Ekinci S; Kale G; Akyüz C; Büyükpamukçu M; Karnak I; Çiftçi AÖ; Tanyel FC; Şenocak ME
    J Pediatr Urol; 2015 Jun; 11(3):118.e1-6. PubMed ID: 25842994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bilateral Wilms' tumor with anaplasia: lessons from the National Wilms' Tumor Study.
    Hamilton TE; Green DM; Perlman EJ; Argani P; Grundy P; Ritchey ML; Shamberger RC
    J Pediatr Surg; 2006 Oct; 41(10):1641-4. PubMed ID: 17011261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome.
    Lahoti C; Thorner P; Malkin D; Yeger H
    Am J Pathol; 1996 May; 148(5):1577-89. PubMed ID: 8623926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of Wilms' tumor in eastern China: 10 years of experience at a single center.
    Yao W; Li K; Xiao X; Gao J; Dong K; Xiao X; Lv Z
    J Invest Surg; 2012 Jun; 25(3):181-5. PubMed ID: 22583015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TP53 codon 72 polymorphisms in favorable histology Wilms tumors.
    Cost NG; Mitui M; Khokhar S; Wickiser JE; Baker LA; Rakheja D
    Pediatr Blood Cancer; 2012 Aug; 59(2):326-8. PubMed ID: 22052810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New definitions of focal and diffuse anaplasia in Wilms tumor: the International Society of Paediatric Oncology (SIOP) experience.
    Vujanić GM; Harms D; Sandstedt B; Weirich A; de Kraker J; Delemarre JF
    Med Pediatr Oncol; 1999 May; 32(5):317-23. PubMed ID: 10219330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cytomorphologic spectrum of Wilms tumour on fine needle aspiration: a single institutional experience of 110 cases.
    Nayak A; Iyer VK; Agarwala S
    Cytopathology; 2011 Feb; 22(1):50-9. PubMed ID: 20236293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.
    Ooms AH; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Ma Y; Zong Z; Mungall AJ; Moore RA; Marra MA; Huff V; Dome JS; Chi YY; Tian J; Geller JI; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Walz AL; van den Heuvel-Eibrink MM; de Krijger RR; Ross N; Gastier-Foster JM; Perlman EJ
    Clin Cancer Res; 2016 Nov; 22(22):5582-5591. PubMed ID: 27702824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p53 immunopositivity in histologically favorable Wilms tumor is not related to stage at presentation or to biological aggression.
    D'Angelo MF; Kausik SJ; Sebo TJ; Rathbun SR; Kramer SA; Husmann DA
    J Urol; 2003 May; 169(5):1815-7. PubMed ID: 12686851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aberrant activation, nuclear localization, and phosphorylation of Yes-associated protein-1 in the embryonic kidney and Wilms tumor.
    Murphy AJ; Pierce J; de Caestecker C; Libes J; Neblett D; de Caestecker M; Perantoni AO; Tanigawa S; Anderson JR; Dome JS; Das A; Carroll TJ; Lovvorn HN
    Pediatr Blood Cancer; 2014 Feb; 61(2):198-205. PubMed ID: 24115727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunohistochemical expression of p53 oncoprotein in Wilms tumour in relation to histological components, histological types and preoperative chemotherapy].
    Djuricić S; Djokić D; Vujić D; Basta-Jovanović G; Todorović V; Radojević-Skodrić S; Zdravković S; Vujanić GM
    Srp Arh Celok Lek; 2008 Dec; 136 Suppl 4():298-306. PubMed ID: 20804099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG).
    Mavinkurve-Groothuis AM; van den Heuvel-Eibrink MM; Tytgat GA; van Tinteren H; Vujanic G; Pritchard-Jones KL; Howell L; Graf N; Bergeron C; Acha T; Catania S; Spreafico F
    Pediatr Blood Cancer; 2015 Apr; 62(4):598-602. PubMed ID: 25546733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Botryoid Wilms tumor: a non-existent "entity" causing diagnostic and staging difficulties.
    Vujanić GM; Schiavo Lena M; Sebire NJ
    Virchows Arch; 2019 Feb; 474(2):227-234. PubMed ID: 30515564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.